drugset / Trial / NCT07297654
First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment
Phase 2
Not yet recruiting
50 enrolled
National Cancer Center, Korea
Asan Medical Center · collabHanyang University Guri Hospital · collabSamsung Medical Center · collabSeoul National University Bundang Hospital · collabSeoul National University Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the efficacy and safety of lenvatinib as first-line therapy in patients with Child-Pugh class B HCC who are unsuitable for curative treatment.
Timeline
- Start
- 2026-02
- Primary completion
- 2028-05
- Completion
- 2028-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |